Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed COO
|
|
STEMLINE THERAPEUTICS INC (STML)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 05/21/2020 |
GN
| SHAREHOLDER ALERT: WeissLaw LLP Reminds STML, PTLA, and QES Shareholders About Its Ongoing Investigations |
| 05/19/2020 |
GN
| STEMLINE ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of STML and Encourages Investors to Contact the Firm |
| 05/19/2020 |
GN
| KLXE, FSB, PTLA, and STML SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers |
| 05/15/2020 |
GN
| Lifshitz Law Firm, P.C. Announces Investigation of KLX Energy Services Holdings, Inc. (KLXE), Quintana Energy Services, Inc. (QES), Portola Pharmaceuticals, Inc. (PTLA), and Stemline Therapeutics, Inc. (STML) |
| 05/14/2020 |
GN
| SHAREHOLDER ALERT: WeissLaw LLP Reminds STML, PTLA, QES, and TERP Shareholders About Its Ongoing Investigations |
| 05/12/2020 |
GN
| KLXE, PTLA, STML, and TORC SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers |
| 05/11/2020 |
GN
| Lifshitz Law Firm, P.C. Announces Investigation of KLX Energy Services Holdings, Inc. (KLXE), Portola Pharmaceuticals, Inc. (PTLA), Stemline Therapeutics, Inc. (STML) and Zuora, Inc. (ZUO) |
| 05/07/2020 |
GN
| KLXE, PTLA, and STML SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers |
| 03/13/2020 |
GN
| Stemline Therapeutics Reports Fourth Quarter 2019 Financial Results |
| 03/11/2020 |
GN
| Stemline Therapeutics to Host Conference Call on Fourth Quarter 2019 Financial Results on March 16, 2020 |
| 02/26/2020 |
GN
| Stemline Therapeutics to Present at the Cowen 40th Annual Health Care Conference |
| 01/13/2020 |
GN
| Stemline Therapeutics Announces Preliminary 2019 Net Revenues for ELZONRIS® (tagraxofusp) and Highlights Commercial and Clinical Growth Drivers |
| 01/08/2020 |
GN
| Stemline Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference |
| 12/06/2019 |
GN
| Stemline Therapeutics Names Robert M. Francomano Chief Commercial Officer |
| 12/06/2019 |
GN
| Stemline Therapeutics Highlights Three ELZONRIS Presentations, Including an Oral Presentation in Myelofibrosis, at Upcoming ASH Meeting |
| 11/29/2019 |
GN
| Stemline Therapeutics to Present at Piper Jaffray's 31st Annual Healthcare Conference |
| 11/07/2019 |
GN
| Stemline Therapeutics Reports Third Quarter 2019 Financial Results |
| 11/06/2019 |
GN
| Stemline Therapeutics Announces Three ELZONRIS Presentations, Including an Oral Presentation in Myelofibrosis, at Upcoming ASH Meeting |
| 10/01/2019 |
GN
| Stemline Therapeutics Recaps Felezonexor (SL-801) Clinical Data Presentation From ESMO 2019 Congress |
| 09/27/2019 |
GN
| Stemline Therapeutics Announces Felezonexor (SL-801) Clinical Data to be Featured at Upcoming ESMO 2019 Congress |
| 09/26/2019 |
GN
| Stemline Therapeutics to Present at the 2019 Cantor Global Healthcare Conference |
| 09/05/2019 |
GN
| Stemline Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference |
| 08/09/2019 |
GN
| Stemline Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference |
| 08/08/2019 |
GN
| Stemline Therapeutics Announces Pricing of $76,250,000 Public Offering of Common Stock |
| 08/07/2019 |
GN
| Stemline Therapeutics Announces Proposed Public Offering of Common Stock |
| 07/08/2019 |
GN
| Stemline Therapeutics Highlights Recent Clinical and Regulatory Developments and Details Upcoming Milestones following its Annual Shareholder Meeting |
| 06/28/2019 |
GN
| The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of Stemline Therapeutics, Inc. Common Stock -- STML |
| 06/17/2019 |
GN
| Stemline Therapeutics Announces Presentation of ELZONRIS (tagraxofusp) Preclinical Data in Systemic Sclerosis, an Autoimmune Disorder, at EULAR Congress |
| 06/13/2019 |
GN
| Stemline Therapeutics Announces Three ELZONRIS (tagraxofusp) Clinical Presentations at EHA Congress June 13-15 |
| 06/03/2019 |
GN
| Stemline Therapeutics Announces ASCO Presentation of ELZONRIS Phase 2 Clinical Data in CMML and MF; Provides Next Steps for CMML Program |
| 05/20/2019 |
GN
| Stemline Therapeutics Announces ELZONRIS Clinical Data Selected for Presentation at Upcoming EHA Annual Congress |
| 05/16/2019 |
GN
| Stemline Therapeutics Announces ELZONRIS Clinical Data Selected for Presentation at the Upcoming ASCO Annual Meeting |
| 05/10/2019 |
GN
| Stemline Therapeutics Reports First Quarter 2019 Financial Results |
| 05/08/2019 |
GN
| Stemline Therapeutics to Host Conference Call on First Quarter 2019 Financial Results on May 10, 2019 |
|
|
|